摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,4,5-triphenyl-1H-pyrazole-1-decanoic acid | 134701-90-9

中文名称
——
中文别名
——
英文名称
3,4,5-triphenyl-1H-pyrazole-1-decanoic acid
英文别名
10-(3,4,5-triphenylpyrazol-1-yl)decanoic acid
3,4,5-triphenyl-1H-pyrazole-1-decanoic acid化学式
CAS
134701-90-9
化学式
C31H34N2O2
mdl
——
分子量
466.623
InChiKey
STPWAVMCNFZELS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    7.9
  • 重原子数:
    35
  • 可旋转键数:
    13
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    55.1
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Arylpyrazol derivatives as anti-platelet agents, compositions and use
    摘要:
    式为##STR1##的化合物,其中R.sup.1和R.sup.2各自独立地为氢或苯基,但R.sup.1和R.sup.2不能同时为氢;m为3至9的整数;n为0至3的整数,m+n的和为5至12的整数;Z为O、S、SO、SO.sub.2、--CH.dbd.CH--或直接键;A为##STR2##R.sup.3为氢或C.sub.1-6烷基;R.sup.4为氢、C.sub.1-4烷基或甲基磺酰基。其药学上可接受的盐或水合物是人血小板富集血浆腺苷酸二磷酸和胶原诱导聚集的新型抑制剂,特别适用于哺乳动物血小板聚集的抑制剂。
    公开号:
    US04994482A1
  • 作为产物:
    描述:
    10-溴代癸酸甲酯sodium hydroxide 、 sodium hydride 作用下, 以 甲醇 为溶剂, 反应 3.0h, 生成 3,4,5-triphenyl-1H-pyrazole-1-decanoic acid
    参考文献:
    名称:
    Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic
    摘要:
    A series of phenylated pyrazoloalkanoic acid derivatives were synthesized and evaluated as inhibitors of ADP-induced human platelet aggregation. 3,4,5-Triphenyl-1H-pyrazole-1-nonanoic acid (8d), with an 1C50 of 0.4-mu-M, was the most potent inhibitor identified in this study. Biochemical studies determined that 8d increased intraplatelet cAMP accumulation and stimulated platelet membrane-bound adenylate cyclase in a concentration-dependent fashion. Displacement of [H-3]iloprost by 8d from platelet membranes indicated that the platelet prostacyclin (PGI2) receptor is the locus of biological action. Structure-activity studies demonstrated that the minimum structural requirements for binding to the platelet PGI2 receptor and inhibition of ADP-induced platelet aggregation within this series are a vicinally diphenylated pyrazole substituted with an omega-alkanoic acid side chain eight or nine atoms long. Potency depended upon both side-chain length and its topological relationship with the two phenyl rings.
    DOI:
    10.1021/jm00080a028
点击查看最新优质反应信息

文献信息

  • Arylpyrazole derivatives as anti-platelet agents
    申请人:Bristol-Myers Squibb Company
    公开号:US05071866A1
    公开(公告)日:1991-12-10
    Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 each are independently hydrogen or phenyl, provided that R.sup.1 and R.sup.2 may not both be hydrogen; m is an integer from 3 to 9; n is an integer from 0 to 3 and the sum of m+n is an integer from 5 to 12; Z is O, S, SO, SO.sub.2, --CH.dbd.CH-- or a direct bond; A is ##STR2## R.sup.3 is hydrogen or C.sub.1-6 alkyl; and R.sup.4 is hydrogen, C.sub.1-4 alkyl or methylsulfonyl; and pharmaceutically acceptable salts or hydrates thereof are novel inhibitors of adenosine diphosphate and collagen-induced aggregation of human platelet-rich plasma and are particularly useful as inhibitors of mammalian blood platelet aggregation.
    公式为##STR1##的化合物,其中R.sup.1和R.sup.2各自独立地为基,前提是R.sup.1和R.sup.2不能都为;m是3到9的整数;n是0到3的整数,m+n的和是5到12的整数;Z为O、S、SO、SO.sub.2、--CH.dbd.CH--或直接键;A为##STR2##;R.sup.3为或C.sub.1-6烷基;R.sup.4为、C.sub.1-4烷基或甲磺酰基;以及其药学上可接受的盐或合物是人血小板富集血浆中腺苷酸二磷酸和胶原诱导聚集的新型抑制剂,特别是哺乳动物血小板聚集的抑制剂
  • Arylpyrazole derivatives as platelet aggregation inhibitors
    申请人:Bristol-Myers Squibb Company
    公开号:EP0417449B1
    公开(公告)日:1995-02-15
  • US4994482A
    申请人:——
    公开号:US4994482A
    公开(公告)日:1991-02-19
  • US5071866A
    申请人:——
    公开号:US5071866A
    公开(公告)日:1991-12-10
查看更多